Chemotherapy-Induced Diarrhea Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Chemotherapy-Induced Diarrhea Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “Chemotherapy-induced diarrhea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chemotherapy-induced diarrhea, historical and forecasted epidemiology as well as the Chemotherapy-induced diarrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Chemotherapy-induced diarrhea Market Insights, Epidemiology, and Market Forecast-2032”  report delivers an in-depth understanding of Chemotherapy-induced diarrhea, historical and forecasted epidemiology as well as the Chemotherapy-induced diarrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.


The Chemotherapy-induced diarrhea market report provides current treatment practices, emerging drugs, the Chemotherapy-induced diarrhea market share of the individual therapies, and current and forecasted Chemotherapy-induced diarrhea market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chemotherapy-induced diarrhea treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the Chemotherapy-induced diarrhea market.

Some of the Key Facts of the chemotherapy-induced Diarrhea Market Report:


  • As per Bossi et al. (2018), diarrhea is a common symptom of the presence of several types of malignant tumors. Gastroenteropancreatic and lung neuroendocrine tumors (NETs) and colorectal cancer are the most frequent diarrhea–associated tumors (20% of the cases).

  • According to J et al. (1998), 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer. Approximately 20-24% of patients in each treatment group were aged 70 years or older and 41% of the patients were female.

  • Immune-mediated diarrhea and colitis (IMDC) are among the most common immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors (ICIs). According to a meta-analysis by Su et al., (2018), PD-1 inhibitors may result in a higher risk of all-grade immune-induced colitis than chemotherapy. Pembrolizumab may result in a higher risk of all-grade immune-mediated colitis than chemotherapy. However, both nivolumab and atezolizumab maybe do not introduce a higher risk of immune-mediated colitis than chemotherapy.


Key Benefits of the Chemotherapy-induced Diarrhea Market Report


  • The report covers a descriptive overview of Chemotherapy-induced diarrhea, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Chemotherapy-induced diarrhea epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Chemotherapy-induced diarrhea is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Chemotherapy-induced diarrhea market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chemotherapy induced diarrhea market

Got queries? Click here to know more about Chemotherapy-induced diarrhea  Market Landscape


Chemotherapy-Induced Diarrhea Overview

Chemotherapy-induced diarrhea (CID) also, referred to as chemotherapy-related diarrhea (CRD) is a common side effect of cancer treatment. While cytotoxic agents are the main cause of CID, targeted drugs, immunotherapy, and radiotherapy can also cause diarrhea.Diarrhea is a common side effect of chemotherapy. It can cause dehydration and malnourishment, making a person feel sick and potentially intensifying other chemo-related side effects.

CID presents a constant challenge in the efficient and tolerable treatment of cancer and is amongst the primary contributors to dose reductions, delays, and cessation of treatment. 

Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease, and infections.


Chemotherapy-Induced Diarrhea Epidemiological Insights:


  • Chemotherapy-induced diarrhea (CID) is a common problem, especially in patients with advanced cancer. According to Stein et al.,(2010) CID can occur in 50–80% of patients depending on the chemotherapy regimen administration and dosage. The therapeutic agents commonly causing diarrhea include 5-fluorouracil (5-FU), capecitabine and irinotecan.

  • For over 30% of CID sufferers it interferes with their daily activities with detrimental effects on the mental and social health of cancer survivors.

  • According to McQuade et al. (2014), although specific chemotherapeutic agents have been correlated with a heightened incidence of GI side effects, incidences as high as 40% in patients receiving standard-dose chemotherapy and 100% in patients receiving high-dose chemotherapy have been reported.

  • Regimens, especially those containing 5-fluorouracil and irinotecan are associated with rates of CID of up to 80%  with one-third of patients experiencing severe (grade 3 or 4) diarrhea. Chemotherapy-induced diarrhea severely interferes with anti-cancer treatment, resulting in treatment alterations in approximately 60% of patients, dose reductions in 22% of patients, dose delays in 28% of patients and complete termination of treatment in 15% of patients 

  • As per Artale et al. (2022), CTID is a frequent complication of chemotherapy and targeted therapy, occurring in more than half of the patients treated for colorectal cancer. Chemotherapy with irinotecan alone and regimens, which are used for metastatic colorectal cancer, were reported to be associated with an increased incidence of grade 3–4 diarrhea ranging from 16% to 23%


Chemotherapy-induced diarrhea Epidemiological Segmentation 


  • Total Chemotherapy-induced diarrhea prevalent cases 

  • Total Chemotherapy-induced diarrhea diagnosed Cases 

  • Tota Chemotherapy-induced diarrhea treatment cases 

  • Total Chemotherapy-induced diarrhea severity-specific cases 


Chemotherapy-Induced Diarrhea Market Outlook 

The Chemotherapy-induced diarrhea market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chemotherapy-induced diarrhea market trends by analyzing the impact of current Chemotherapy-induced diarrhea therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chemotherapy-induced diarrhea market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chemotherapy-induced diarrhea market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Chemotherapy-induced diarrhea market in 7MM is expected to witness a major change in the study period 2019-2032.


Learn more by requesting for sample @ Chemotherapy-Induced Diarrhea Market Landscape

Chemotherapy-Induced Diarrhea Key Companies

  • Napo Pharmaceuticals

  • OnQuality Pharmaceuticals

  • And many more 

Chemotherapy-Induced Diarrhea Therapies 


  • OQL051

  • And many others 

Table of Contents


  1.   Key Insights 

  2.   Report Introduction 

  3.   Executive Summary of Chemotherapy-induced diarrhea   

  4.   Disease Background and Overview

  5.   Epidemiology and patient population

  6.   The United States 

  7.   EU 5

  8.   Chemotherapy-induced diarrhea Emerging Therapies

  9.   Chemotherapy-induced diarrhea Market Outlook

  10.   Market Drivers 

  11.   Market Barriers 

  12.   Market Access and Reimbursement of Therapies

  13.   Appendix

  14.   Chemotherapy-induced diarrhea    Report Methodology

  15.   DelveInsight Capabilities

  16.   Disclaimer

  17.   About DelveInsight

Click here to read more about Chemotherapy-induced diarrhea Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States